kabutan

CanBas Co.,Ltd.(4575) Summary

4575
TSE Growth
CanBas Co.,Ltd.
795
JPY
-3
(-0.38%)
Mar 13, 3:30 pm JST
4.98
USD
Mar 13, 2:30 am EDT
Result
PTS
outside of trading hours
795
Mar 13, 11:27 pm JST
Summary Chart Historical News Financial Result
PER
PBR
6.69
Yield
ー%
Margin Trading Ratio
Stock Price
Mar 13, 2026
Opening Mar 13, 9:03 am
779 JPY 4.89 USD
Previous Close Mar 12
798 JPY 5.01 USD
High Mar 13, 2:53 pm
797 JPY 5.00 USD
Low Mar 13, 9:07 am
774 JPY 4.86 USD
Volume
139,600
Trading Value
0.11B JPY 0.69M USD
VWAP
784.57 JPY 4.92 USD
Minimum Trading Value
79,500 JPY 498 USD
Market Cap
0.02T JPY 0.10B USD
Number of Trades
380
Liquidity & Number of Trades
As of Mar 13, 2026
Liquidity
High
1-Year Average
1,217
1-Year High Aug 21, 2025
19,409
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 6, 2026 0 1,262,500
Feb 27, 2026 0 1,343,700
Feb 20, 2026 0 1,393,100
Feb 13, 2026 400 1,525,300 3813.25
Feb 6, 2026 0 1,516,800
Company Profile
CanBas Co., Ltd. is a drug discovery venture specializing in anticancer drug development. Its primary source of income is research and development support funds. The company is actively seeking partnership opportunities.
Sector
Pharmaceuticals
CanBas Co., Ltd. is a drug discovery venture focusing on basic research, early clinical development, and late-stage clinical development of anticancer drugs. Leveraging its unique drug discovery approach, the company has a development pipeline consisting of multiple drug candidate compounds. CanBas utilizes external specialized institutions and a scientific advisory board, aiming for synergy by combining in-house development with strategic partnerships with pharmaceutical companies. The company's lead compound, CBP501, is currently undergoing Phase 2 clinical trials in combination with immune checkpoint inhibitor antibodies. CBS9106 has been licensed to a U.S. company and is progressing through clinical development. In addition to these, CanBas is conducting exploratory research on multiple novel candidate compounds. The company's immediate priorities are accelerating the development of CBP501 and maximizing its chances of success, while continuing basic research to deepen understanding of existing pipelines and generate next-generation pipelines. Continuous fundraising through direct financing is also positioned as one of the company's challenges and strategies to support these efforts.